ライフサイエンスコーパス: photocoagulation

1 fter 5 monthly doses (2q8), or macular laser photocoagulation.

2 in photodynamic therapy (vPDT); or (4) laser photocoagulation.

3 ement or confirmation of complete panretinal photocoagulation.

4 of other nonmedical treatments such as laser photocoagulation.

5 ithout a history of peripheral retinal laser photocoagulation.

6 IOP elevation in mice was achieved by laser photocoagulation.

7 urs, 3 days, 14 days, and 28 days post-laser photocoagulation.

8 itial monthly doses (2PRN), or macular laser photocoagulation.

9 scularization was treated with scatter laser photocoagulation.

10 e the kinetics of FAF recovery after retinal photocoagulation.

11 elevated in Wistar rats by translimbal laser photocoagulation.

12 therapeutic cellular response to focal laser photocoagulation.

13 sthetized cats underwent retinal argon laser photocoagulation.

14 erapy the only available treatment was laser photocoagulation.

15 e perifovea in one eye were ablated by laser photocoagulation.

16 CNV was induced in rats by laser photocoagulation.

17 nti-CD144, or control, before or after laser photocoagulation.

18 ls is to rupture Bruch's membrane with laser photocoagulation.

19 ents and fluorescein angiography after laser photocoagulation.

20 that drusen may resolve after macular laser photocoagulation.

21 sponds poorly to focal or grid-pattern laser photocoagulation.

22 fter 5 monthly doses (2q8), or macular laser photocoagulation.

23 effectively treated with percutaneous laser photocoagulation.

24 ucose solution with dialysis and pan-retinal photocoagulation.

25 perative emesis and intraoperative extensive photocoagulation.

26 tcomes two months after treatment with laser photocoagulation.

27 t were subsequently treated with focal laser photocoagulation.

28 nctive cryotherapy, intracameral cautery, or photocoagulation.

29 e identified HS was treated with focal laser photocoagulation.

30 in eyes that are nonresponsive to panretinal photocoagulation.

31 s were treated with ranibizumab plus scatter photocoagulation.

32 (71/407) of patients were eligible for laser photocoagulation.

33 imited benefit of macular grid-pattern laser photocoagulation (1 citation).

34 (topical and/or systemic) or underwent laser photocoagulation (29%) and/or surgery (55.6%).

35 in 8 patients included vitrectomy (1), laser photocoagulation (4), intravitreal bevacizumab (5), intr

36 thout PDR at baseline, (3) having panretinal photocoagulation, (4) experiencing vitreous hemorrhage,

37 laterally by repeated trabecular argon laser photocoagulation 5 days after intracameral injection of

38 Laser photocoagulation (532-nm wavelength, 200-mW power, 0.05-

39 available for the role of macular grid laser photocoagulation (7) and scatter peripheral laser surger

40 tinal ischemia, which was treated with laser photocoagulation after retinal reapplication.

41 ation is best managed by applying panretinal photocoagulation after the first appearance of iris neov

42 ents with newly diagnosed CSDME: focal laser photocoagulation alone (L), focal laser plus intravitrea

43 etic retinopathy (PDR) usually is panretinal photocoagulation, an inherently destructive treatment th

44 and a controlled, randomized trial of laser photocoagulation and aspirin treatment in diabetic retin

45 xpert specialists for consideration of laser photocoagulation and for echocardiography to evaluate si

46 ll mice at 24, 72, and 168 hours after laser photocoagulation and from unlasered eyes and were tested

47 he posterior eye are mostly treated by laser photocoagulation and multiple intraocular injections, pr

48 RVO-associated macular edema was grid laser photocoagulation and observation for central RVO-associa

49 ded the site of laser injury within 1 day of photocoagulation and peaked at 3 days.

50 CNV lesions were generated using laser photocoagulation and quantified by imaging; T-lymphocyte

51 urrent treatment modalities, including laser photocoagulation and repeated intraocular injection of V

52 fluid, no cardiovascular disease, no scatter photocoagulation, and male gender, whereas in sham-treat

53 onsteroidal inflammatory agents, argon laser photocoagulation, and photodynamic therapy have been eff

54 Photodynamic therapy, laser photocoagulation, and transpupillary thermotherapy may b

55 ons such as enucleation, radiotherapy, laser photocoagulation, and transpupillary thermotherapy or a

56 s with BRVO and 9 with CRVO received scatter photocoagulation, and with mean follow-up of 9 months (B

57 mbined with standard treatments (e.g., laser photocoagulation), anti-inflammatory agents, or other no

58 izumab, intravitreal triamcinolone and laser photocoagulation appear to transiently decrease macular

59 lial growth factor injections and panretinal photocoagulation are important to prevent neovascular gl

60 s administered every 6 weeks with focal/grid photocoagulation at investigator discretion after week 1

61 so received angiography-guided macular laser photocoagulation at month 1 and again every 3 months for

62 vea of the treated eye were ablated by laser photocoagulation at the start of the diffuser-rearing pe

63 , the Bruch's membrane was ruptured by laser photocoagulation at three sites in each eye.

64 neovascularization is not amenable to laser photocoagulation because this would cause a blinding cen

65 four (27%) of 127 eyes with complete scatter photocoagulation before undergoing PPV compared with 22

66 22 (48%) of 46 eyes with incomplete scatter photocoagulation before undergoing PPV demonstrated post

67 e modalities exist including stenting, laser photocoagulation, brachytherapy, and chemotherapy used s

68 ition, 14 pigmented rats were treated with 3 photocoagulation burns in their right eyes.

69 because both selective targeting and thermal photocoagulation can be realized.

70 Therapeutic retinal laser photocoagulation can damage the neurosensory retina and

71 Subthreshold micropulse retinal laser photocoagulation caused equivalent histologic changes fr

72 o determine whether carefully titrated laser photocoagulation combined with vitrectomy and gas tampon

73 with carefully titrated juxtapapillary laser photocoagulation combined with vitrectomy and gas tampon

74 al implant (DEX implant) combined with laser photocoagulation compared with laser alone for treatment

75 on studies unequivocally show the benefit of photocoagulation compared with observation in reducing t

76 ual acuity improvement, increased panretinal photocoagulation completion rates, and reduced recurrent

77 us hemorrhage from PDR precluding panretinal photocoagulation completion.

78 different levels of energy using diode laser photocoagulation coupled with an intraocular laser probe

79 ry thermotherapy, proton beam therapy, laser photocoagulation, CyberKnife radiation, or photodynamic

80 er of macula thickness, application of focal photocoagulation) did not show a consistent trend in fav

81 cate carefully titrated juxtapapillary laser photocoagulation followed by vitrectomy with gas tampona

82 went carefully titrated juxtapapillary laser photocoagulation followed immediately by vitrectomy and

83 l anti-VEGF therapy is as effective as laser photocoagulation for achieving regression of acute ROP.

84 reatment for diabetic retinopathy; (3) laser photocoagulation for branch retinal vein obstruction; (4

85 and without angiography-guided macular laser photocoagulation for center-involving diabetic macular e

86 stria), 13 patients (13 eyes) underwent grid photocoagulation for diabetic maculopathy.

87 al interventions of the following: (1) laser photocoagulation for exudative macular degeneration; (2)

88 in Occlusion Study randomized trial of laser photocoagulation for macular edema and for the managemen

89 lycemic and blood pressure control and laser photocoagulation for neovascularization and clinically s

90 Grid-pattern laser photocoagulation for perfused macular edema did not show

91 Infants treated with laser photocoagulation for severe ROP should be monitored with

92 al choroidal neovascularization, while laser photocoagulation for the same entity confers a 4.4% impr

93 Anti-VEGF therapy is superior to laser photocoagulation for treatment of moderate to severe vis

94 panretinal photocoagulation (PRP) and focal photocoagulation (FP) compared with fundus photography.

95 ession was identified in the CNVM induced by photocoagulation from day 5 (16.2% +/- 6.8% of the lesio

96 After the first laser photocoagulation, GGA was administered twice a week.

97 extend with angiography-GuIded macular LAser photocoagulation (GILA; n = 60).

98 cizumab (IVB), both combined with grid laser photocoagulation (GLP) for macular edema (ME) secondary

99 ith retinal sparing may be possible if focal photocoagulation, guided by an MRI map, is performed.

100 s study did not show that grid-pattern laser photocoagulation had a significant beneficial effect for

101 Although laser photocoagulation has been the standard treatment for DME

102 lial growth factor therapy and laser retinal photocoagulation, have limitations and are associated wi

103 53E (MBCU), and no prior panretinal or focal photocoagulation in at least one eye at baseline.

104 CNV was induced by laser photocoagulation in C57BL/6 and Cd59a(-/-) mice using an

105 CNV was induced by laser photocoagulation in C57BL/6 mice using an argon laser, a

106 CNV was induced by laser photocoagulation in C57BL/6 mice.

107 One week after krypton laser photocoagulation in C57BL/6J mice, 34 of 60 burns (57%)

108 (NPDR) that underwent navigated focal laser photocoagulation in DME and were followed at 3, 6, and 1

109 alized retinal changes following focal laser photocoagulation in DME treatment.

110 reduction in CRT at 24 weeks than grid laser photocoagulation in eyes with macular edema after BRVO.

111 eye and subthreshold 532-nm micropulse laser photocoagulation in their left eye.

112 d subthreshold 810-nm diode micropulse laser photocoagulation in their right eye and subthreshold 532

113 ts of intravitreal injection of TRO on laser photocoagulation-induced CNV lesions in rat eyes (15 exp

114 ibility of gene transduction targeted to the photocoagulation-induced CNVM was demonstrated using ret

115 Then, beta-gal expression in each photocoagulation-induced CNVM was examined by observing

116 ectomy alone without gas tamponade and laser photocoagulation is a safe and effective method for mana

117 Demarcation laser photocoagulation is associated with less morbidity than

118 a (DME) with vision loss after macular laser photocoagulation is clinically valuable.

119 a (DME) with vision loss after macular laser photocoagulation is clinically valuable.

120 Panretinal photocoagulation is designed to increase retinal PO2 by

121 Ablative laser photocoagulation is indicated for very selected cases of

122 neovascularization suggested that grid laser photocoagulation is not useful for the improvement of vi

123 Treatment for PDR, panretinal photocoagulation, is inherently destructive and has sign

124 ravitreal injection, focal laser, panretinal photocoagulation, laterality of procedure, ranibizumab,

125 bit retina were destroyed by selective laser photocoagulation, leaving retinal inner neurons (bipolar

126 cord intraretinal Po(2) profiles from healed photocoagulation lesions in anesthetized cats breathing

127 After 1 day, the intraretinal photocoagulation lesions were sharply demarcated, wherea

128 Hyperthermia with infrared irradiation below photocoagulation level produces tumor necrosis with few

129 eated with intravitreal bevacizumab or laser photocoagulation (LPC) and untreated eyes.

130 One study suggests that laser photocoagulation may be useful in prophylactically treat

131 Subthreshold micropulse photocoagulation may decrease this risk by selective tis

132 avitreal anti-VEGF medication and panretinal photocoagulation may help to prevent additional vision l

133 ompt location and destruction of the worm by photocoagulation, may improve the vision of affected pat

134 sed ROP following bilateral panretinal laser photocoagulation (n = 37; median gestational age [GA] =

135 aocular pressure (IOP) was elevated by laser photocoagulation of episcleral and limbal veins.

136 The method also may permit selective photocoagulation of feeding vessels in the choroid, ther

137 retinal reattachment, and the time to laser photocoagulation of ischemic retina.

138 s induced unilaterally in CD-1 mice by laser photocoagulation of limbal and episcleral veins 270 degr

139 Laser photocoagulation of limbal and episcleral veins induces

140 s induced unilaterally in CD-1 mice by laser photocoagulation of limbal and episcleral veins.

141 Selective laser photocoagulation of retinal telangiectasia at the retina

142 high-pressure glaucoma was produced by laser photocoagulation of the anterior chamber angle in 38 eye

143 aterally in 13 NIH Black Swiss mice by laser photocoagulation of the limbus.

144 he time to retinal reapplication until laser photocoagulation of the nonperfusion areas could be perf

145 ous of rabbits and pigs (but not cats) after photocoagulation of the outer retina.

146 Multiple CNV lesions were induced by laser photocoagulation of the retina in Brown-Norway rats.

147 In more severe conditions, direct endolaser photocoagulation of the telangiectasia was required.

148 as induced unilaterally by translimbal laser photocoagulation of the trabecular meshwork in Sprague-D

149 rtension was induced in a rat model by laser photocoagulation of the trabecular meshwork.

150 del of glaucoma was used that involved laser photocoagulation of the trabecular meshwork.

151 A rat model of glaucoma with laser photocoagulation of trabecular meshwork was used.

152 sion was introduced by rose Bengal and laser photocoagulation on chimeric mice that were reconstitute

153 g intravenous fluorescein angiography, laser photocoagulation, optical coherence tomography, ophthalm

154 acular edema, and the need for intervention (photocoagulation or anti-VEGF) over 18 years of follow-u

155 Panretinal photocoagulation or intravitreous ranibizumab injections

156 t reportedly does not respond well to either photocoagulation or photodynamic therapy (PDT).

157 eiving either ranibizumab plus scatter laser photocoagulation or ranibizumab alone for an additional

158 e nata, aflibercept 2.0 mg bi-monthly, laser photocoagulation or sham.

159 m creatinine (>291.7 micromol/L), or retinal photocoagulation or vitrectomy (first composite outcome)

160 steroids, intravitreal ganciclovir and laser photocoagulation or vitrectomy.

161 R, 3.27; P = .005), extensive intraoperative photocoagulation (OR, 4.94; P < .001), and emesis postop

162 l growth factor (VEGF) injection, panretinal photocoagulation, or both for retinal ischemia.

163 gs, including vitrectomy, cryotherapy, laser photocoagulation, or photodynamic therapy, were excluded

164 vely (P < .001) and extensive intraoperative photocoagulation (P < .001).

165 Laser photocoagulation parameters can be specified to avoid no

166 Unlike standard laser photocoagulation, photodynamic therapy can close choroid

167 ) and therapeutic interventions (argon laser photocoagulation, photodynamic therapy, intravitreal cor

168 of this study was to determine whether laser photocoagulation produces a similar increase in photorec

169 Cryotherapy and photocoagulation provide excellent control of small tumo

170 b, sub-Tenon's triamcinolone, and panretinal photocoagulation (PRP) after cataract surgery (instead o

171 validity of self-report of prior panretinal photocoagulation (PRP) and focal photocoagulation (FP) c

172 Panretinal photocoagulation (PRP) for proliferative diabetic retino

173 nopathy has been managed by panretinal laser photocoagulation (PRP) for the past 40 years.

174 Pan retinal photocoagulation (PRP) has provided an effective treatme

175 Panretinal photocoagulation (PRP) is the standard treatment for red

176 opathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab.

177 gnosed high-risk PDR treated with panretinal photocoagulation (PRP) using either argon green laser (4

178 Panretinal laser photocoagulation (PRP) was shown to be beneficial for ey

179 asonable treatment alternative to panretinal photocoagulation (PRP) when managing proliferative diabe

180 ts including PPV, injections, and panretinal photocoagulation (PRP), as well as visual acuity at base

181 on graded fundus photographs, (2) panretinal photocoagulation (PRP), or (3) pars plana vitrectomy (PP

182 omewhat disorganized, as in human panretinal photocoagulation (PRP).

183 hy (PDR), previously treated with panretinal photocoagulation (PRP).

184 Laser photocoagulation remains a safe and effective therapy, b

185 Destruction of damaged retina by photocoagulation remains the primary treatment nearly 50

186 ression of neovascularization, scatter laser photocoagulation remains the standard of care to prevent

187 While focal laser photocoagulation remains the standard of care, a new wav

188 is offered, and if the tumor is small, laser photocoagulation, resection, or thermotherapy can be use

189 tion of microaneurysms following focal laser photocoagulation resulted in hyperreflective spots and c

190 roups based on outcome after confluent laser photocoagulation: retinal detachment or favorable outcom

191 otoma correlating with the site of the laser photocoagulation scar, and subfoveal choroidal neovascul

192 Use of laser photocoagulation significantly declined for treatment of

193 and without angiography-guided macular laser photocoagulation significantly decreased the number of i

194 key eyes (n = 20), matrix placement of laser photocoagulation sites elicited CNV as a component of th

195 Overall, 65% of the photocoagulation sites in the squirrel monkey and 37% of

196 iffuse FVT that expanded beyond the original photocoagulation sites, accompanied by neovascular infil

197 The macular photocoagulation studies unequivocally show the benefit

198 a median absolute difference of 0.19 Macular Photocoagulation Study disc areas (DA) in total atrophy

199 The Macular Photocoagulation Study has received praise for its many

200 eovascularization by argon laser pan-retinal photocoagulation successfully managed IOP increase durin

201 oward eye-saving procedures, including laser photocoagulation, surgical removal of tumor, and techniq

202 of 263 participants in a trial comparing two photocoagulation techniques for DME.

203 Laser photocoagulation then was applied to the trabecular mesh

204 There was a good uptake of laser photocoagulation therapy among patients affected by DR i

205 etinopathy, and assess the outcomes of laser photocoagulation therapy in a diabetic population in Cam

206 ents (a composite of requirement for retinal photocoagulation therapy or vitrectomy, development of p

207 thy of prematurity (ROP) compared with laser photocoagulation therapy.

208 th elevated IOP, induced by trabecular laser photocoagulation, there was a significant loss of Rbpms-

209 ucleation, radiotherapy, chemotherapy, laser photocoagulation, thermotherapy, and cryotherapy.

210 ved ophthalmic treatment (cryotherapy, laser photocoagulation, thermotherapy, or plaque radiation the

211 ved away from submacular surgery and macular photocoagulation to antivascular endothelial growth fact

212 The addition of scatter photocoagulation to ranibizumab PRN may reduce progressi

213 Here we use photocoagulation to selectively destroy photoreceptors i

214 eyes with severe nonperfusion received laser photocoagulation to the nonperfused retina; laser-treate

215 rior segment neovascularization, until laser photocoagulation to the reapplied retina could be perfor

216 Adding angiography-guided laser photocoagulation to this dosing algorithm did not signif

217 ter month 40 received scatter and grid laser photocoagulation to try to reduce the need for injection

218 chronic DME despite at least one focal laser photocoagulation treatment (nine eyes) received 4 L/min

219 omic outcomes in a subgroup of macular laser photocoagulation treatment control (hereafter laser cont

220 omic outcomes in a subgroup of macular laser photocoagulation treatment control (hereafter laser cont

221 substantial vision loss after macular laser photocoagulation treatment for DME.

222 substantial vision loss after macular laser photocoagulation treatment for DME.

223 irmed that the angle was closed by the laser photocoagulation treatment.

224 as evidenced by a greater number of macular photocoagulation treatments and less reduction in SD OCT

225 Panretinal photocoagulation treatments declined from 109 840 proced

226 The mean number of macular photocoagulation treatments in Cohorts 1, 2, 3, and 4 wa

227 thickness (CMT), and mean number of macular photocoagulation treatments over the 2-year study period

228 30), TReat and EXtend without macular laser photocoagulation (TREX; n = 60), and treat and extend wi

229 2 maculae of seven squirrel monkeys by laser photocoagulation using optimized laser parameters (532 n

230 main outcome was incident DR requiring laser photocoagulation, vitrectomy, and/or antiangiogenic ther

231 Focal/grid laser photocoagulation was added after 6 months if DME persist

232 Focal/grid laser photocoagulation was administered in 41%, 64%, and 52%,

233 Laser photocoagulation was administered in 75 eyes (62.0%), ou

234 Laser photocoagulation was applied to the mouse fundus using a

235 Laser photocoagulation was performed at the slit lamp or durin

236 Laser photocoagulation was performed in wild-type and knockout

237 Panretinal photocoagulation was shown to be beneficial for eyes wit

238 Slit-lamp laser photocoagulation was sufficient in half of the cases.

239 Laser photocoagulation was then applied to the trabecular mesh

240 Laser photocoagulation was then applied to the trabecular mesh

241 Laser photocoagulation was used to induce CNV in C57BL/6J mice

242 Laser photocoagulation was used to induce CNV in wild-type C57

243 Laser photocoagulation was used to induce CNV in wild-type C57

244 Bruch's membrane rupture by laser photocoagulation was used to induce CNV.

245 Laser photocoagulation was used to induce CNVM in rats.

246 Translimbal laser photocoagulation was used to induce unilateral IOP eleva

247 Laser photocoagulation was used to produce unilateral experime

248 Laser photocoagulation was used to rupture Bruch's membrane in

249 ous injections of bevacizumab and panretinal photocoagulation were administered, the new vessels regr

250 ring treatment with an intravitreal agent or photocoagulation) were significantly higher (hazard rati

251 Endoscopic photocoagulation, while more technically challenging and

252 re treated in one institution by using laser photocoagulation with combined computed tomographic (CT)

253 % CI, -4% to 13%) and of complete panretinal photocoagulation without vitrectomy by 16 weeks was 44%

254 After laser photocoagulation, WT mice showed significantly greater V

255 H and was associated with incomplete scatter photocoagulation, younger age, and phakia before PPV.